The impact of cholecalciferol on markers of vascular calcification in hemodialysis patients: A randomized placebo controlled study.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

Vascular calcification is an independent risk factor for cardiovascular diseases and all-cause mortality in end stage renal disease, and particularly in hemodialysis patients.

Cholecalciferol or vitamin D3; the native inactivated 25-hydroxy vitamin D [25(OH)D], has been proposed to have a good impact on vascular calcification and vitamin D deficiency.

However, clinical data is still limited.

Who Took Part

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

How the Study Was Run

The design is described as randomized and single-blind.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Only one side, usually the participants, was kept unaware of whether Vitamin D, K2, Magnesium and Zinc was given.

What Was Measured

The subject headings attached to it are Biomarkers, Cholecalciferol, Egypt, Fibroblast Growth Factor-23, Kidney Diseases, Renal Dialysis and Vascular Calcification.

Author keywords: 25(OH)D, FGF-23, Fetuin-A, Hemodialysis and OPG.

What This Means in Plain Language

The paper is a randomized and single-blind study of Vitamin D, K2, Magnesium and Zinc.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2021 (Nutrition, metabolism, and cardiovascular diseases : NMCD), a journal based in Netherlands.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.